Regulatory Submission

Phase 3

We use the review window to get you launch-ready. The months your submission spends under review are either preparation or lost time, and the difference shows the day clearance arrives.

Phase Overview

Regulatory Submission begins when a company files its regulatory package with the FDA, whether a 510(k), De Novo request, or PMA, and ends when the agency issues its decision. For 510(k) submissions that window is typically three to twelve months. For PMA submissions it can extend considerably longer. While the submission is under review the company is in a waiting period that carries real commercial risk. Teams that use the time well arrive at clearance with commercial strategy fully prepared and stakeholders already engaged. Teams that don't experience a slow and costly start to commercial launch.

HCP Pre-Awareness Campaigns

Disease-state and unmet-need campaigns that build clinician awareness ahead of clearance, without making product claims.

Payer & Health System Messaging

Reimbursement and value messaging refined and pressure-tested with the audiences who control access.

Web Design & Development

The commercial website designed and built so it's ready to go live rather than starting after clearance.

Sales Enablement

Branded content and tools developed to equip commercial teams to engage clinicians, payers, and procurement leaders.

Campaign Development

Multichannel launch campaigns developed and staged, ready to activate on the day authorization is granted.

Manufacturing Feasibility

The design assessed against real production constraints to determine how, and whether, it can be manufactured at target volumes.

Content Production

Educational assets, presentations, and sales materials produced across the audiences launch will need to reach.

Media Planning

Channels identified, budgets allocated, and the launch media plan built against your clearance timeline.

Explainer Videos

Concise, high-impact video that breaks down your innovation for clinicians, investors, and patients.

Why This Phase Matters

Review time is the only period in the entire journey where the commercial team has capacity and a known deadline. Companies that treat it as a pause spend the first quarter after clearance building what they could have built while waiting, and they cede that quarter to competitors and to the general inertia of clinical adoption. Companies that treat it as a runway launch into a market that already knows the problem they solve. The regulatory outcome is out of your hands. Readiness isn't.

NEXT PHASE

Market Clearance

With the decision granted and commercial assets prepared, your program moves into Market Clearance, where strategy activates and the team prepares to go to market.

Continue